Colchicine and Quality of Life in Patients With Acute Coronary Syndromes: Results From the COPS Randomized Trial.

Cardiovasc Revasc Med

Department of Cardiology, Peninsula Health, Melbourne, Victoria, Australia; Department of Medicine, Monash University, Melbourne, Victoria, Australia. Electronic address:

Published: November 2022

AI Article Synopsis

  • Colchicine may reduce cardiovascular events in patients with acute coronary syndromes, prompting this study to investigate its effects on health status outcomes in the Australian COPS trial.
  • The trial involved 786 patients, with health status assessed using the EQ-5D-5L and the Seattle Angina Questionnaire at baseline and 12 months; while overall health scores improved, there were no significant differences between colchicine and placebo groups.
  • However, colchicine treatment was associated with a higher likelihood of improvement in physical limitation scores, suggesting some positive impact on patients' physical health.

Article Abstract

Background: Recent data suggest that colchicine may reduce cardiovascular events among patients presenting with acute coronary syndromes. This sub-study of the Australian COPS trial aimed to assess whether colchicine affects health status outcomes.

Methods: Health status was assessed at baseline and 12-months using the EuroQol-5 Dimension 5-level (EQ-5D-5L) score and the full 19-question Seattle Angina Questionnaire (SAQ). Data were available for 786 patients (388 randomized to colchicine, 398 to placebo).

Results: Baseline characteristics were well matched between groups; mean age was 60.1 (SD 14.8) years, and 20 % were female. Baseline health status scores were impaired, and most parameters demonstrated significant improvement from baseline to 12-months (EQ-5D-5L Visual Analogue Score [VAS] 69.3 to 77.7; SAQ angina frequency score 83.0 to 95.3, both p < 0.001). No significant differences in adjusted mean score change among any of the EQ-5D-5L or SAQ dimensions were observed between treatment groups in either intention-to-treat or per-protocol analysis. There were borderline interactions in EQ-5D-5L scores for those with previous MI vs not, and in SAQ scores for those with obesity vs not. In categorical analysis using observed data, patients treated with colchicine were more likely to have clinically significant improvement in physical limitation score over the period (36 % improved vs. 28 %, p < 0.05). Baseline health status scores were not associated with the primary endpoint at 12 months.

Conclusions: Treatment with colchicine did not appear to affect change in measures of health status following acute coronary syndromes, but it did lead to a greater likelihood of improvement in physical limitation scores.

Trial Registration: ACTRN, ACTRN12615000861550. Registered 18/08/2015, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368973.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.carrev.2022.06.017DOI Listing

Publication Analysis

Top Keywords

health status
20
acute coronary
12
coronary syndromes
12
baseline 12-months
8
baseline health
8
status scores
8
improvement physical
8
physical limitation
8
colchicine
6
health
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!